LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

21.71 5.08

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.92

Максимум

21.71

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+86.74% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	600M 1.7B
Предишно отваряне	16.63
Предишно затваряне	21.71

Настроения в новините

By Acuity

65%

35%

297 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.02.2026 г., 23:53 ч. UTC

Горещи акции

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27.02.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27.02.2026 г., 17:55 ч. UTC

Горещи акции

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27.02.2026 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27.02.2026 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.02.2026 г., 21:30 ч. UTC

Печалби

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27.02.2026 г., 21:30 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27.02.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27.02.2026 г., 21:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27.02.2026 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27.02.2026 г., 21:09 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27.02.2026 г., 21:00 ч. UTC

Печалби

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27.02.2026 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27.02.2026 г., 20:24 ч. UTC

Пазарно говорене

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27.02.2026 г., 20:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27.02.2026 г., 20:12 ч. UTC

Пазарно говорене

Nike Seen With Further Challenges in China -- Market Talk

27.02.2026 г., 19:44 ч. UTC

Пазарно говорене

Gold Caps Historic Month -- Market Talk

27.02.2026 г., 19:39 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27.02.2026 г., 19:38 ч. UTC

Печалби

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27.02.2026 г., 18:53 ч. UTC

Придобивния, сливания и поглъщания

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27.02.2026 г., 18:45 ч. UTC

Печалби

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27.02.2026 г., 18:45 ч. UTC

Пазарно говорене

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.02.2026 г., 17:07 ч. UTC

Печалби

Pemex Cuts 4Q Loss As Operating Results Improve

27.02.2026 г., 17:00 ч. UTC

Пазарно говорене

Corn Rides Oil Momentum Higher -- Market Talk

27.02.2026 г., 16:31 ч. UTC

Пазарно говорене

Canadian Economy Shows Resilience -- Market Talk

27.02.2026 г., 16:17 ч. UTC

Пазарно говорене

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27.02.2026 г., 15:49 ч. UTC

Печалби

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

86.74% нагоре

12-месечна прогноза

Среден 38.6 USD 86.74%

Висок 56 USD

Нисък 28 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

297 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.